Normal tissue effects: reporting and analysisSøren M. Bentzen, John T. Williams, Wolfgang Dörr et al.|Seminars in Radiation Oncology|2003Cited by 140
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i>-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S. Anscher, Julia A. Beaver, Oluseyi Adeniyi et al.|The Oncologist|2020Cited by 74
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Harpreet Singh, Lijun Zhang et al.|The Lancet Oncology|2021Cited by 15
Metastasis free survival in older men with nonmetastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: An FDA-pooled analysis.Harpreet Singh, Julia A. Beaver, Lijun Zhang et al.|Journal of Clinical Oncology|2020Cited by 0
Statin Inhibits Radiation-Induced Fibrosis through Regulation of CTGF/IGFBP-rP2 Action in Lung FibroblastsAki Harada, Youngman Oh, Wei Li et al.|Unknown|2011Cited by 0